Shares

15 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 04, 2023

BUY
$19.47 - $28.49 $537,391 - $786,352
27,601 Added 6.09%
480,918 $10.9 Million
Q4 2022

Feb 02, 2023

BUY
$18.08 - $30.0 $301,610 - $500,460
16,682 Added 3.82%
453,317 $10.7 Million
Q3 2022

Nov 14, 2022

BUY
$22.51 - $34.32 $424,088 - $646,588
18,840 Added 4.51%
436,635 $11.4 Million
Q2 2022

Aug 12, 2022

BUY
$16.0 - $45.99 $4.81 Million - $13.8 Million
300,550 Added 256.34%
417,795 $9.17 Million
Q1 2022

May 09, 2022

BUY
$33.17 - $46.98 $839,532 - $1.19 Million
25,310 Added 27.53%
117,245 $5.26 Million
Q4 2021

Feb 10, 2022

SELL
$39.06 - $67.58 $153,857 - $266,197
-3,939 Reduced 4.11%
91,935 $3.94 Million
Q3 2021

Nov 09, 2021

SELL
$60.13 - $77.6 $50,930 - $65,727
-847 Reduced 0.88%
95,874 $6.38 Million
Q2 2021

Aug 12, 2021

BUY
$50.07 - $76.78 $2.46 Million - $3.77 Million
49,103 Added 103.12%
96,721 $7.09 Million
Q1 2021

May 12, 2021

BUY
$58.92 - $97.33 $740,977 - $1.22 Million
12,576 Added 35.89%
47,618 $3.26 Million
Q4 2020

Feb 12, 2021

SELL
$43.6 - $73.05 $247,342 - $414,412
-5,673 Reduced 13.93%
35,042 $2.35 Million
Q3 2020

Nov 12, 2020

BUY
$38.47 - $52.03 $47,510 - $64,257
1,235 Added 3.13%
40,715 $2.1 Million
Q2 2020

Aug 04, 2020

BUY
$27.28 - $43.01 $1.08 Million - $1.7 Million
39,480 New
39,480 $1.49 Million
Q1 2020

May 04, 2020

SELL
$23.08 - $35.53 $1.25 Million - $1.93 Million
-54,183 Closed
0 $0
Q4 2019

Feb 10, 2020

BUY
$15.74 - $35.04 $14,874 - $33,112
945 Added 1.78%
54,183 $1.86 Million
Q3 2019

Oct 22, 2019

BUY
$18.09 - $27.92 $963,075 - $1.49 Million
53,238 New
53,238 $963,000

Others Institutions Holding CSTL

About CASTLE BIOSCIENCES INC


  • Ticker CSTL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 26,297,000
  • Market Cap $723M
  • Description
  • Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...
More about CSTL
Track This Portfolio

Track Essex Investment Management CO LLC Portfolio

Follow Essex Investment Management CO LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Essex Investment Management CO LLC, based on Form 13F filings with the SEC.

News

Stay updated on Essex Investment Management CO LLC with notifications on news.